Bionet (1784) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Bionet TWD 16.69, price TWD 61.30, upside -72.8%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bionet for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 35.10 TWD – 161.50 TWD · fair‑value band 9.87 TWD – 17.93 TWD · the 61.30 TWD price screens above the 16.69 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bionet in your weekly email
Every Wednesday you see whether Bionet is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services.
Show more
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.
Stock analysis
Bionet (1784) currently trades at 61.30 TWD, while our model-based Fair Value estimate is 16.69 TWD, implying the stock looks roughly 267.2% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 19.52 TWD per share, and 0 of the 22 models we run sit above the 61.30 TWD price.
Bear case: the Earnings-Based group reads lowest at 7.04 TWD, and 22 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 9.87 TWD (bear) to 17.93 TWD (bull), the price of 61.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bionet reported revenue of 1.2B TWD in FY2025 versus 921M TWD in FY2021, a compound +7.6%/yr. Reported net income was 51.4M TWD in FY2025, compounding +17.9%/yr from FY2021.
Key figures
Market cap 3.1B TWD (≈ $96.8M) · P/E ratio 53.8 · P/S ratio 2.24 · EPS (TTM) 1.14 TWD · Dividend yield 1.4% · Net margin 4.2% · Return on equity −0.2% · Return on assets (EBIT) 2.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, 1784 screens richer than that median.
Fair Value models
Bear 9.87 TWDFair Value 16.69 TWDBull 17.93 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.1982 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.7%
Dividend (yield on the price)1.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → −1%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +53.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−73% · Bottom 25%
Profitability
Return on assets0% · Below median
Net margin (TTM)4% · Above median
Operating margin (TTM)−2% · Below median
Growth and dividend
Revenue growth8% · Above median
Dividend yield (TTM)1.4% · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)53.8× · Pricier than median
P/B2.47× · Pricier than median
P/S (TTM)2.49× · Pricier than median
P/FCF6.2× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)41· sector 25
PAST (return on equity)0· sector 8
HEALTH (low debt)0· sector 95
DIVIDEND (yield)28· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bionet Fair Value". https://www.fairvalue-calculator.com/stock/1784
Frequently asked questions
Is Bionet (1784) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 16.69 TWD versus a price of 61.30 TWD, about −73% upside (overvalued).
What is the fair value of 1784?
Our model-based fair value for Bionet is 16.69 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 61.30 TWD.
What is the quality score of 1784?
Bionet has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bionet (1784)?
Our model-based price target is the fair value of 16.69 TWD (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 9.87 TWD, optimistic scenario 17.93 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Bionet stock forecast for 2026?
Our models put fair value at 16.69 TWD, about −73% upside versus a price of 61.30 TWD (overvalued). Cautious scenario 9.87 TWD, optimistic scenario 17.93 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Bionet (1784)?
Bionet reported trailing-twelve-month revenue of about 1.3B TWD (latest available figure, as of Sep 24, 2026).
Does Bionet pay a dividend?
Bionet currently shows a dividend yield of about 1.42% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Bionet (1784)?
For today's price to be fair in a discounted-cash-flow model, Bionet would have to grow free cash flow by +55.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1784 use?
Our models discount Bionet at 11.8 %: a base by market capitalisation (micro), damped by beta 0.56, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bionet that is +55.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Bionet (1784) delivered so far?
Over the past 5 years revenue at Bionet grew +8.9 % a year. The price currently implies +55.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bionet (1784) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bionet (+55.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bionet (1784)?
The free-cash-flow yield on the price is 0.51 %: that much free cash flow Bionet produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bionet (1784)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bionet it is 16.69 TWD per share (as of Sep 24, 2026), against a price of 61.30 TWD. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Bionet stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1784 trades above its calculated fair value: price 61.30 TWD, fair value 16.69 TWD, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1784?
No. The price is what the market pays today (61.30 TWD); the fair value is what the company's own numbers justify (16.69 TWD). For Bionet the two are 44.61 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Bionet worth?
The market values Bionet at about 3.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 61.30 TWD; our models calculate a fair value of 16.69 TWD per share.
What do the bullish and bearish scenarios say about 1784?
Our models span a range for Bionet: cautious scenario 9.87 TWD, base 16.69 TWD, optimistic 17.93 TWD per share (as of Sep 24, 2026, price 61.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1784?
Bionet trades at a price-to-earnings ratio of 53.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 16.69 TWD is built from several models across several years. Other multiples: P/B 2.5, P/S 2.5.
How solid is the balance sheet of Bionet (1784)?
Balance-sheet figures for Bionet (as of Sep 24, 2026): return on equity −0.2%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 1784 from its 52-week high?
Bionet trades at 61.30 TWD, about 47% below its 52-week high of 115.50 TWD and 9% above the low of 56.10 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 16.69 TWD is for.
Which stocks are comparable to Bionet?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bionet stock attractive at the current price?
The data as of Sep 24, 2026: price 61.30 TWD, calculated fair value 16.69 TWD (−73%), Quality Score 48/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1784 calculated?
We run Bionet through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 16.69 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Bionet itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bionet (1784)?
The closing price on Sep 24, 2026 was 61.30 TWD. Our model-based fair value is 16.69 TWD, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bionet right now?
The price sits above even our optimistic bull case (17.93 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (9.87 TWD to 17.93 TWD) leaves room in how you read the outcome.
Key figures of Bionet
How large is the market capitalisation of Bionet (1784)?
The market capitalisation of Bionet is 3.1B TWD (≈ $96.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bionet (1784)?
The price-to-sales ratio of Bionet is 2.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bionet (1784)?
Earnings per share at Bionet are 1.14 TWD (price ÷ EPS = P/E 53.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bionet (1784)?
The dividend yield of Bionet is 1.4% (payout 76.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bionet (1784)?
The net margin of Bionet is 4.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bionet (1784)?
The return on equity (ROE) of Bionet is −0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bionet (1784)?
On an EBIT basis the return on assets of Bionet is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bionet (1784)?
The operating margin of Bionet is −1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bionet (1784)?
Revenue at Bionet is growing +8.2% versus a year earlier (3y avg +8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bionet (1784)?
Earnings per share at Bionet are growing −16.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Bionet (1784) hold?
Bionet holds more cash than debt, 193M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Bionet in the live analysis
One click puts Bionet on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
